Recently, we could show that expression of HH pathway transcription factors GLI1 and GLI2 represents a negative prognostic marker for patients with AML and targeted inhibition of GLI1/2 mediates anti-leukemic effects in vitro and in vivo. Here, GLI2 is linked to acute myeloid leukemia.